🔍

VALIANTORG - Valiant Organics

📊 NSE: VALIANTORG 🏢 Chemicals 📅 Last Updated: 12/14/2025 14:54

📢 Recent Corporate Announcements

Valiant Organics Q3 FY26 Net Profit Rises 30.5% YoY to ₹6.06 Cr; Exceptional Gain of ₹5.72 Cr

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 13 Feb 2026, 05:02 PM

Valiant Organics reported a standalone net profit of ₹6.06 crore for the quarter ended December 31, 2025, marking a 30.5% increase from ₹4.65 crore in the previous year's corresponding quarter. While revenue from operations declined 14.8% year-on-year to ₹159.07 crore, the company showed sequential stability. Profitability was significantly aided by an exceptional gain of ₹5.72 crore from a fire insurance claim settlement. Notably, the company has achieved a turnaround for the nine-month period, posting a profit of ₹19.24 crore compared to a loss of ₹6.95 crore in the prior year period.

Standalone Net Profit increased to ₹6.06 crore in Q3 FY26 from ₹4.65 crore in Q3 FY25.
Revenue from operations stood at ₹159.07 crore, a slight sequential increase from ₹157.21 crore in Q2 FY26.
Recognized an exceptional gain of ₹5.72 crore relating to a fire insurance claim settlement for the Sarigam Division.
Finance costs decreased significantly to ₹4.56 crore compared to ₹5.83 crore in the same quarter last year.
9-month FY26 standalone profit reached ₹19.24 crore, reversing a net loss of ₹6.95 crore in 9M FY25.

💡 Investors should note the company's successful turnaround into profitability and the reduction in finance costs, which indicates better debt management. Monitor the execution of the new manufacturing agreement with Aarti Pharmalabs for potential long-term revenue growth.

Valiant Organics Q3 Standalone Net Profit Rises 30.5% YoY to ₹6.06 Cr; Revenue Dips 14.8%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 13 Feb 2026, 05:00 PM

Valiant Organics reported a standalone net profit of ₹6.06 crore for Q3 FY26, a 30.5% increase from ₹4.65 crore in the same quarter last year, despite a 14.8% decline in revenue to ₹159.07 crore. The bottom line was significantly bolstered by an exceptional gain of ₹5.72 crore from a fire insurance claim settlement related to a past fire incident. For the nine-month period ended December 2025, the company achieved a major turnaround with a profit of ₹19.24 crore compared to a loss of ₹6.95 crore in the previous year. Finance costs also saw a healthy reduction, dropping to ₹4.56 crore from ₹5.83 crore YoY.

Standalone Net Profit grew 30.5% YoY to ₹6.06 crore, aided by a ₹5.72 crore exceptional insurance gain.
Revenue from operations fell 14.8% YoY to ₹159.07 crore, though it showed a marginal 1.2% growth on a QoQ basis.
9M FY26 performance shows a sharp recovery with a net profit of ₹19.24 crore versus a loss of ₹6.95 crore in 9M FY25.
Finance costs for the quarter reduced by 21.8% YoY to ₹4.56 crore, reflecting improved debt management.
Basic EPS improved significantly to ₹2.16 in Q3 FY26 from ₹1.18 in the corresponding quarter of the previous year.

💡 The company has successfully turned around from last year's losses, though the YoY revenue decline suggests ongoing pricing or volume pressure in the chemicals sector. Investors should monitor if core operational profitability can be sustained in the absence of one-time insurance gains.

Valiant Organics Clarifies Single Segment Operations for Q2 FY26 Financial Results

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 05 Feb 2026, 11:08 AM

Valiant Organics Limited has provided a formal response to a clarification sought by the National Stock Exchange (NSE) regarding its financial results for the quarter ended September 30, 2025. The exchange had flagged the non-submission of consolidated segment details as a deficiency. The company clarified that it operates as a single-segment entity focused solely on the manufacturing of chemicals. Consequently, management stated there are no separate reportable business segments to disclose in the consolidated financial statements under SEBI regulations.

NSE sought clarification on January 13, 2026, regarding missing consolidated segment reporting for the Sept 2025 quarter.
Company confirms it operates exclusively in a single business segment: chemical manufacturing.
Management asserts that no separate reportable segments exist for consolidated financial reporting purposes.
The clarification was issued promptly on the same day the query was received from the exchange.

💡 This is a routine regulatory clarification with no impact on the company's financial health or business strategy. Investors should focus on the core chemical manufacturing margins and volume growth in upcoming earnings.

Valiant Organics Reports Full Dematerialization Compliance for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Jan 2026, 05:20 PM

Valiant Organics Limited has submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025. The company's Registrar and Share Transfer Agent, MUFG Intime India Pvt. Ltd., confirmed that no requests for dematerialization were received during this period. This is attributed to the fact that 100% of the company's securities are already held in dematerialized form. This filing is a standard regulatory procedure and confirms the company's adherence to depository norms.

Compliance certificate issued for the quarter and nine months ended December 31, 2025.
Registrar MUFG Intime India confirmed zero dematerialization or mutilation requests were received.
100% of the company's equity shares are currently held in electronic (dematerialized) form.
The filing confirms adherence to SEBI (Depositories and Participants) Regulations, 2018.

💡 No action is required from investors as this is a routine regulatory filing. Investors should continue to monitor the company's upcoming quarterly financial performance.

Valiant Organics Announces Trading Window Closure from January 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Dec 2025, 11:19 AM

Valiant Organics Limited has informed the stock exchanges that its trading window will be closed starting January 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the announcement of financial results for the quarter ending December 31, 2025. The restriction applies to all directors, promoters, and designated persons. The window will reopen 48 hours after the financial results are officially declared.

Trading window closure effective from Thursday, January 1, 2026.
Closure pertains to the financial results for the quarter ended December 31, 2025.
Restriction covers Directors, Promoters, Designated Persons, and their immediate relatives.
Window to remain closed until 48 hours after the declaration of financial results.

💡 This is a routine regulatory filing with no direct impact on company fundamentals; investors should await the upcoming quarterly financial results.

View All VALIANTORG Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue for FY 2025 was INR 7,187.62 million, representing a slight decline of 0.59% from INR 7,230.59 million in FY 2024. However, H1-FY26 showed a recovery with revenue reaching INR 3,617 million, a 10.2% increase YoY. Business segments include Hydrogenation, Chlorination, and Ammonolysis, serving Dyes, Pharma, and Agro industries.

Geographic Revenue Split

The company serves both domestic and international markets, leveraging strategic plant locations near ports to facilitate exports, though specific percentage splits per region are not disclosed in the available documents.

Profitability Margins

Consolidated PAT margins improved significantly to 3.84% in H1-FY26 compared to a negative margin of 3.99% in H1-FY25. Standalone PAT for Q2-FY26 was INR 56 million with a 3.56% margin, recovering from a loss of INR 112 million in Q2-FY25.

EBITDA Margin

Consolidated EBITDA margin for H1-FY26 stood at 12.69%, a substantial increase of 714 bps from 5.55% in H1-FY25. Standalone EBITDA margin for Q2-FY26 reached 13.49% compared to just 1.44% in the previous year's quarter.

Capital Expenditure

Standalone capital expenditure for FY 2025 was INR 12.49 crore, a reduction of 25.8% from the INR 16.85 crore spent in FY 2024. These investments were primarily directed toward property, plant, and equipment.

Credit Rating & Borrowing

The company maintains a 'Negative' outlook from credit agencies due to tepid demand. Finance costs for FY 2025 rose to INR 23.64 crore from INR 19.38 crore in FY 2024, an increase of 22% YoY. Ratings are sensitive to operating margins staying above 12-14%.

⚙️ Operational Drivers

Raw Materials

The company utilizes chemical inputs for Hydrogenation, Chlorination, and Ammonolysis processes to produce specialty chemicals and intermediates, though specific chemical names like benzene or phenol are not explicitly listed in the provided text.

Capacity Expansion

Current installed capacity is not specified in MT; however, the company continues to invest in PPE with a FY25 standalone spend of INR 12.49 crore to maintain production capabilities.

Raw Material Costs

Total consolidated expenses for H1-FY26 were INR 315.8 crore, representing 87.3% of revenue, compared to INR 309.9 crore in H1-FY25.

Manufacturing Efficiency

Efficiency is reflected in the EBITDA margin recovery to 12.69% in H1-FY26 from 5.55% YoY, suggesting improved cost absorption or a better product mix.

Logistics & Distribution

Logistics costs are optimized via port-proximate manufacturing sites, which the company identifies as a key driver for competitive pricing and delivery speed.

📈 Strategic Growth

Expected Growth Rate

10.20%

Growth Strategy

Growth is targeted through a diverse product portfolio of intermediates and value-added products. The strategy involves leveraging high-quality standards and innovative production capabilities to capture demand in the Pharma and Agro-chemical sectors while maintaining logistical cost advantages.

Products & Services

Specialty chemical intermediates and value-added products used in the manufacturing of Dyes, Pigments, Pharmaceuticals, and Agro-chemicals.

Brand Portfolio

Valiant Organics Limited (VOL).

Market Expansion

The company is focusing on both domestic and international markets, utilizing its port-based strategic locations to expand its global footprint.

Strategic Alliances

The company reported a share of profit from associates amounting to INR 0.7 crore in H1-FY26, compared to a loss of INR 1.8 crore in H1-FY25.

🌍 External Factors

Industry Trends

The specialty chemicals industry is currently experiencing tepid demand, which has constrained margins; however, VOL is positioning itself through process-based segments like Hydrogenation and Ammonolysis.

Competitive Landscape

The company faces competitive pressures that could impact its ability to maintain operating margins above the 12% threshold required for credit rating upgrades.

Competitive Moat

The company's moat is based on its strategic port-side plant locations (logistical cost leadership) and a diverse, integrated product portfolio that serves multiple critical industries like Pharma and Agro.

Macro Economic Sensitivity

Highly sensitive to the global demand cycles of the pharmaceutical and agrochemical industries, as well as macroeconomic trends affecting the specialty chemicals sector.

Consumer Behavior

Demand is driven by industrial B2B cycles in the pharmaceutical and agricultural sectors rather than direct retail consumer trends.

Geopolitical Risks

Exposure to international trade dynamics due to its export-oriented port locations and reliance on global end-user industry health.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Taxation Policy Impact

The company's consolidated tax expense for H1-FY26 was INR 4.6 crore on a PBT of INR 18.5 crore, reflecting an effective tax rate of approximately 24.8%.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the duration of the 'tepid demand' phase in end-user industries, which could keep operating margins below 8% and lead to further credit downgrades.